To define the effects of pregnancy on mechanical properties and reactivity, mesenteric veins from late pregnant and virgin control (nonpregnant) rats were pressurized to determine gestational changes in size and distensibility. Reactivity studies used an adrenergic constrictor (norepinephrine) and an endotheliummediated vasodilator (acetylcholine). The contribution of nitric oxide to endothelial function was evaluated with pharmacologic inhibition of nitric oxide synthase. Roles of nitric oxide and cyclic guanosine monophosphate in smooth muscle vasodilation were determined using an nitric oxide donor with and without cyclic guanosine monophosphate inhibition using ODQ, a selective inhibitor of guanylyl cyclase. In pregnancy, endothelium-dependent vasodilation markedly increased (largely due to endogenous nitric oxide), smooth muscle response to nitric oxide decreased (primarily related to cyclic guanosine monophosphate production), and norepinephrine sensitivity decreased considerably, with no changes in vessel size or distensibility. Our results identify a provasodilatory state in the systemic venous system, which would serve to facilitate the accommodation to plasma volume expansion requisite for normal pregnancy.
D uring pregnancy, the maternal cardiovascular system undergoes profound changes to allow for reproductive success. 1, 2 At the level of the maternal vasculature, these adaptations require changes in both structure and behavior (reactivity), [3] [4] [5] [6] which assist in tolerance of a significant increase in intravascular volume. Likewise, failure to establish complete cardiovascular adaptation to plasma volume expansion can have profound implications for developing pregnancy, as seen in pathologic states such as pre-eclampsia and intrauterine growth restriction. [7] [8] [9] The mesenteric circulation, which includes the blood supply to the large and small intestines as well as to the liver and spleen, has been found to hold up to one fourth of the total blood volume. [10] [11] [12] [13] Studies focused on the arterial side of the mesenteric circulation have documented significant changes during pregnancy, including decreased adrenergic (sympathetic) reactivity 3, 14, 15 and enhanced endothelium-dependent vasodilation. 16 Much less is known about venous adaptations, although changes in the compliance and reactivity of this circuit could cause marked changes in cardiac output and capacitance. The limited data that are available show increased adrenergic sensitivity, 17, 18 and there have been no published studies that address changes in endothelial or smooth muscle function.
This study was therefore designed to investigate the effects of pregnancy on mechanical properties and endothelial and smooth muscle responsiveness of systemic veins. The use of isolated, pressurized venous segments allowed us to evaluate changes in size and distensibility, and to probe endothelial versus smooth muscle mechanisms involved in the regulation of venous tone. In view of previously reported changes in mesenteric arterial reactivity and biomechanics, as well as documented tolerance of large plasma volume expansion in normal pregnancy, 19 we hypothesized that pregnancy would increase venous compliance (and therefore size) and augment vasodilatory reserve.
MATERIALS AND METHODS

Animals
Age-matched cycling virgin (nonpregnant [NP], n ¼ 20) and timed-pregnant (late pregnant [LP], n ¼ 21) female Sprague-Dawley rats (Charles River, Canada), were housed at the University of Vermont College of Medicine Animal Facility and were studied at 15.2 + 0.8 weeks of age. Rats were maintained on a 12-hour light and dark photoperiod and were provided with food and water ad libitum. Estrous cycle stage was determined in the NP rats by examining the cell composition of vaginal smears on the day of vessel harvest. The study protocol was approved by the University of Vermont Animal Care and Use Committee. Pregnant animals were studied on day 20 of a 22-day gestation.
Animals were killed by decapitation after a surgical plane of anesthesia was induced using an intraperitoneal injection of pentobarbital sodium (Nembutal 50 mg/mL; Ovation Pharmaceuticals, Deerfield, IL). The abdominal cavity was then opened, and a section of gut 5 to 10 cm distal to the pylorus, and its entire mesenteric circulation was excised and pinned in a Petri dish containing cold (4 C) physiologic N-2-hydroxyethylpiperazine-N 0 -2ethanesulfonic acid (HEPES)-buffered saline solution (pH ¼ 7.4).
Tissue Preparation and Vasograph System
Second-order mesenteric vein branches from an area 5 to 10 cm from the pylorus were dissected free of surrounding fat and connective tissue. Vein segments 2 to 3 mm long were mounted on 2 glass microcannulas within the chamber of a 5-mL vasograph filled with HEPES buffer. The vein was secured with 1 strand of nylon suture (diameter 10 mm) to the proximal microcannula that was connected to an in-line pressure transducer and servo system (Living Systems Instrumentation, Burlington, VT). The vein was initially perfused with physiologic HEPES saline solution (37 C) with a proximal pressure of 2 mm Hg to flush any residual luminal contents. The distal end of the vein was then cannulated and secured in the same manner. A stopcock that was distal to the cannula remained closed throughout the experiment to prevent flow. Venous wall integrity was assessed by ensuring that the system would maintain a transmural pressure of 6 mm Hg for 2 minutes under no flow conditions with the servo null pressure feedback system turned off. If pressure decreased during that time, the vein segment was removed and another segment from the same region of the mesentery was dissected and cannulated.
Vessel diameter was defined as the distance between the internal edges of each vessel wall and measured perpendicular to the long axis of the wall. A complete description of the lumen-diameter analyzing system has been previously published. 20, 21 Several specimens were also submitted to the University of Vermont Imaging Center for evaluation of venous microstructure via transmission electron microscopy. The tissue preparation protocol has been discussed in detail in a previous publication from our laboratory. 5 
Experimental Protocol
Vessels were equilibrated for 45 minutes in a physiologic HEPES saline solution with propranolol (1 mmol/L) added to block b-receptors and to ensure the response seen with norepinephrine (NE) was due to a-stimulation only. The concentration of propranolol used has been established in previous mesenteric venous studies to effectively block venous b-adrenergic receptors. 17 During this time, the solution was warmed and maintained at 37 C. All experiments were performed at 6 mm Hg intraluminal pressure and without intraluminal flow.
After vessel equilibration, NE was added to the circulating solution in increasing concentrations between 1 nmol/L and 10 mmol/L. After 5 to 15 minutes at each concentration, the stable vessel diameter was recorded on the video imaging system. Pharmacologic efficacy (NP, n ¼ 7; LP, n ¼ 8) was evaluated by comparing maximal constriction to NE to that obtained in a depolarizing high potassium (80 mmol/L) solution at the end of each experiment, using the formula: (ø i -ø NE )/ (ø i -ø Kþ ) Â 100, where ø i is the initial diameter, ø NE is the diameter at each NE concentration, and ø Kþ is the diameter in high potassium solution. Pharmacologic sensitivity was also determined by calculating the concentration of NE required to produce half of the response seen at the maximal concentration of NE (median effective concentration [EC 50 ]).
In additional experiments (NP, n ¼ 6; LP, n ¼ 6), vessels were preconstricted to 50% to 70% of the initial diameter with NE, and a concentration response curve to acetylcholine (ACh) was obtained (1 nmol/L to 10 mmol/L). As with NE, efficacy was determined by relating the diameter at each ACh concentration to the maximal diameter possible, measured in a vessel relaxing solution (diltiazem 10 mmol/L and papaverine 100 mmol/L) at the end of the experiment, using the formula: (ø ACh -ø i )/ (ø dp -ø i ) Â 100, where ø ACh is the diameter at each ACh concentration, ø i is the initial constricted diameter, and ø dp is the fully relaxed diameter. Sensitivity was then calculated as already described and expressed by determining the EC 50 .
In those experiments where nitric oxide (NO) inhibition was undertaken (NP, n ¼ 4; LP, n ¼ 6), vessels were initially treated (after NE preconstriction) with a test dose of 1 mmol/L ACh to confirm that a functional vascular endothelium was present. Following washout and re-equilibration, vessels were then incubated for 20 minutes, with a combination of N-nitro-L-arginine (L-NNA, 200 mmol/L) and N o -nitro-L-arginine methyl ester (L-NAME, 200 mmol/L) to provide inhibition of NO production 22 reconstricted with NE and tested with ACh as detailed above.
The effects of pregnancy on venous smooth muscle sensitivity to NO was directly assessed by obtaining dilatory responses to an NO donor 2,2 0 -(hydroxynitrosohydrazono)-bis-ethanimine diethylenetriamine/nitric oxide adduct (DETA/NO). 23, 24 As detailed above, vessels were equilibrated (NP, n ¼ 6; LP, n ¼ 6), preconstricted with NE to 50% to 70% of the initial diameter, subjected to eNOS inhibition (L-NNA) for 20 minutes prior to the administration of DETA/NO; pharmacologic sensitivity to DETA/NO was calculated by comparing vessel diameters at each concentration of DETA/ NO to the maximal response seen with DETA/NO, using the formula (ø D -ø i )/(ø Dmax -ø i ) Â 100, where ø D is the diameter at each DETA/NO concentration, ø i is the initial constricted diameter, and ø Dmax is the maximum diameter response seen to DETA/NO. Efficacy was compared by determining maximal relaxation in DETA/NO to the fully relaxed diameter in a relaxing solution of papaverine þ diltiazem.
Several recent reports have documented NO effects being mediated independently of the cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signaling pathway (eg, p38-MAPK activation 25 and K channels 26 ) in other cell types. 27, 28 Hence, we used a selective inhibitor of soluble guanylyl cyclase, 1H- [29] [30] [31] [32] which was added to the superfusate after maximal dilation with DETA/NO was observed (NP, n ¼ 6; LP, n ¼ 6), to determine proportional inhibition of DETA/NO dilation.
Following determinations of reactivity, distensibility (NP, n ¼ 7; LP, n ¼ 9) was evaluated in the relaxing solution by lowering transmural pressure until the vessel began to collapse, usually at 1 mm Hg, and then increasing pressure just enough to determine the diameter of the vessel under inflated but unstressed conditions at 2 mm Hg. Transmural pressure was then increased in a stepwise fashion over a range of 2 to 10 mm Hg. Lumen diameter was allowed to stabilize for 5 minutes after each increase in pressure. Distensibility (%) was calculated by using the following equation: ø TMP /ø initial , where ø TMP is the diameter at that particular transmural pressure and ø initial at the lowest pressure at which inflation was observed.
Drugs and Solutions
The HEPES physiologic salt solution contained the following (in mmol/L): sodium chloride 141.8, potassium chloride 4.7, magnesium sulfate 1.7, calcium chloride 2.8, potassium phosphate 1.2, HEPES 10.0, EDTA 0.5, and dextrose 5.0). High potassium (80 mmol/L) HEPES solution contained the following (in mmol/L): sodium chloride 63, potassium chloride 78.8, magnesium sulfate 1.7, calcium chloride 2.8, potassium phosphate 1.2, HEPES 10.0 L, EDTA 0.5, and dextrose 5.0. Both solutions were prepared in deionized water and titrated with sodium hydroxide to a physiologic pH of 7.4. Norepinephrine hydrochloride and acetylcholine hydrochloride (Sigma, St Louis, MO) were administered from stock solutions prepared daily in deionized water. All chemicals were purchased from Fisher Scientific (Fair Lawn, NJ) and Sigma unless otherwise specified.
Statistical Analysis
All data are expressed as means + SE. Norepinephrine efficacy is presented relative to maximal vessel constriction to a depolarizing high potassium (80 mmol/L) HEPES solution, and sensitivity is presented relative to maximal vessel constriction to NE, as already described. Acetylcholine and DETA/NO efficacies are presented relative to maximal vessel dilation with relaxing solution, and sensitivities are presented relative to maximal dilation to each agent. Sensitivity was determined by constructing a concentrationresponse curve for each vessel, and then extrapolating to the concentration that produced 50% of the maximum effect (EC 50 ). Data are shown as the average of the individual EC 50 values + SE. The results were analyzed with Student t-test or Mann-Whitney rank sum test for paired observations, and a 1-way ANOVA for multiple comparisons. A P value of <.05 was considered statistically significant.
RESULTS
Vessel Parameters
Venous diameter at a physiologic pressure (6 mm Hg) was unchanged in pregnancy (NP ¼ 426 + 30, LP ¼ 403 + 25 mm, P ¼ .58). Likewise, venous distensibility over a physiologic range of pressure was similar in veins from both pregnant and NP animals (P > .05, Figure 1 ).
Transmission electron microscopy (TEM) was performed on vein segments from both pregnant and nonpregnant animals to evaluate wall ultrastructure. Appearance was similar in both, and a photomicrograph of a longitudinal section through the wall of a vein from a pregnant animal is shown in Figure 2 . Examination revealed an endothelial layer separated from a single layer of vascular smooth muscle by a well-defined elastic lamina and a thick adventitial layer composed of loosely arranged bundles of collagen fibers.
a-Adrenergic Reactivity
Norepinephrine produced marked reductions in the lumen diameters of veins from both groups, with similar efficacies (NP ¼ 75.8 + 3.6%, LP ¼ 62.3 + 8.8%, P > .05; Figure 3 ). Sensitivity to NE was significantly decreased in pregnancy (EC 50 : NP ¼ 56 + 12, LP ¼ 209 + 57 nmol/L, P ¼ .04). When the NP group was separated by estrous cycle stage (proestrus ¼ 4, 
Endothelium-dependent Vasodilation
The maximal dilation seen in response to ACh increased significantly during pregnancy (NP ¼ 35.8 + 6.4%, LP ¼ 60.2 + 7.8%, P ¼ .04, Figure 4 ) as did sensitivity (EC 50 : NP ¼ 935 + 422, LP ¼ 194 + 60, nmol/L, P ¼ .03). In response to ACh, neither group reached the maximum dilation response as seen with diltiazem and papaverine.
Contribution of NO to ACh-induced Reactivity
After preincubation with nitric oxide synthase inhibitors L-NNA and L-NAME, the maximal dilatory response to ACh was significantly attenuated in both study groups (NP ¼ 63 + 6.0%, LP ¼ 67.7 + 6.0% reduction in response to ACh, P < .05, Figure 5 ), although there was no statistically significant difference in the residual dilation after NO blockade between groups (P > .05).
Smooth Muscle Response to NO and Inhibition of cGMP
A significant decrease in vascular smooth muscle sensitivity to DETA/NO was observed during pregnancy with a significant increase in the amount of DETA/NO required to produce 50% of the maximal dilatory response (EC 50 : NP ¼ 16 + 0.9, LP ¼ 27 + 0.9 mmol/L, P < .005, Figure 6 ). The effects of DETA/ NO administration were largely reversed by ODQ in both the pregnant (P < .05) and NP groups (P < .001), although some residual dilation was present, and did not differ between groups (P > .05, Figure 7 ).
DISCUSSION
Maternal plasma volume expands significantly during pregnancy, with average increases of 40% to 50% for singleton pregnancies, 33 and much higher values in multiple gestations. 34 Although changes in the arterial system to allow for tolerance of this volume overload have been well studied, much less is known about the venous side of the circulation, which contains more than two-thirds of the total blood volume. In addition to their roles in capacitance, venous tone and distensibility are important determinants of cardiac return and output. And although only a handful of studies have examined changes in venous distensibility or reactivity during gestation, an association between a failure to adapt and pre-eclampsia has already been noted.
To our knowledge, this is the first study to specifically identify a significant increase in systemic venous endothelium-dependent vasodilation in pregnancy. This was evidenced by increases in both the sensitivity and magnitude of effect of ACh in veins from pregnant animals. These findings are consistent with pregnancy-associated increases in endothelium-dependent vasodilation previously noted in mouse 15 and rat 16, 35 uterine and mesenteric arteries as well as in ovine 36 and human 37 uterine arteries. Although the underlying mechanism is not known, these adaptive changes may be hormonally regulated, as the vasodilation seen exclusively in pregnancy in the guinea pig uterine artery can be reproduced in the NP state by chronic administration of estradiol. 4, 38 Endothelium-induced vasodilation involves multiple pathways that include NO, cyclooxygenase, and endothelium-derived hyperpolarizing factor (EDHF). 39, 40 Using ACh, a standard probe for endothelial vasodilator function, our data indicate that NO plays a primary role, with a >60% decrease in vasodilatory response observed in the presence of NO inhibition. These findings are consistent with experiments on human uterine arteries, which have shown an increase in NO-dependent dilator responses during pregnancy associated with both increased expression and activity of endothelial NO synthase (eNOS). 41, 42 The residual (non-NO) component was similar in vessels from pregnant and NP animals, and further experiments are required to identify the specific contributions of prostanoids versus EDHF in this effect.
The importance of augmented NO release by the endothelium is underscored by the fact that vascular smooth muscle sensitivity to DETA/NO, an NO donor, was reduced in veins from pregnant animals. This compensatory downregulation of smooth muscle NO sensitivity has been noted previously in the uterine artery in response to sodium nitroprusside and may represent a form of nitrate tolerance in response to increased endothelial NO signaling in the pregnant state. 43 As seen in the TEM image, second-order mesenteric veins contain only a single layer of smooth muscle cells. In spite of this, the contractile ability of isolated veins was impressive, as evidenced by the approximately 75% decreases in lumen diameter (in both groups) in response to an 80 mmol/L potassium depolarizing solution, with approximately 60% constriction noted in response to the maximal concentrations of NE. Other studies have documented a rich sympathetic innervation of mesenteric veins, lending physiological credibility to sympathetic regulation of tone. 44 In addition, one report demonstrated NO-containing nerves as well, suggesting that the level of tone may be determined by a balance of vasodilatory and vasoconstrictor nerves, 45 in addition to endothelial and humoral influences.
Although vasodilation to NO is thought to be primarily mediated by cGMP signaling, several recent studies have documented activation of non-cGMP pathways in response to NO stimulation of cardiac myocytes 26, 28 and bovine granulosa cells. 27 To explore this possibility further, we used ODQ, a well-established inhibitor of guanylyl cyclase. Small (<30%) but measurable residual dilation was observed in the presence of supra-maximal concentrations of ODQ, raising the possibility that non-cGMP mechanisms may operate in venous vascular smooth muscle as well, and contribute to venodilation.
Also consistent with a pro-vasodilatory state was our finding of a blunted adrenergic venous constrictor response. Our results do differ from earlier work in our laboratory, which showed an increased constrictor response to NE in mesenteric veins. 18 This may be largely explained by our inclusion of b-adrenergic blockade in our protocol. We were trying to specifically identify the effect of a-adrenergic stimulation, and b-receptor stimulation of mesenteric vessels has been shown to cause vasodilation 46 and may thereby have altered our earlier results. In addition, results similar to our current finding of decreased venous a-adrenergic sensitivity have been seen in vivo studies of human dorsal hand veins in pregnancy. There was no evidence for an effect of estrus cycle on venous NE sensitivity in this study, although the n values were relatively low, and all the animals were only in estrus or proestrus. Estrogen is known to affect arterial vasodilation to other agonists, for example, vascular endothelial growth factor, 47 however, and measurement of serum estradiol would allow for potential correlation between estradiol levels and decreasing a-adrenergic sensitivity.
Increased endothelial vasodilatory influence may be the primary venous adaptation to volume expansion in pregnancy, as there were no parallel changes in venous mechanical or structural characteristics. There was no change in vessel diameter, which contrasts with the changes seen in uterine veins in late pregnancy 5 but is consistent with previous data on mesenteric veins. 18, 48 Likewise, there were no significant differences in passive distensibility, although the trend toward less distensibility was similar to that seen previously in mesenteric veins in both pregnancy and the postpartum period. 17, 48 Despite the limitations of isolated vessel experiments, we are encouraged by the identification of vessel changes in vitro, which support the maternal tolerance of large plasma volume increase as identified in normal pregnancy in vivo. 46, 49 It appears that venous adaptations in pregnancy favor a pro-vasodilatory state in which a-adrenergic responsiveness is decreased, coupled with an increase in endothelial-dependent vasodilatory responsiveness which appears to be primarily mediated by an NO-dependent mechanism. In addition, there is downregulation of smooth muscle response to NO, which is largely related to cGMP production, and this is likely compensated for by increases in NO production and/or availability. The combination of increased vasodilation and decreased a-adrenergic sensitivity would enhance venous capacitance and thereby accommodate the plasma volume increases seen in normal pregnancy.
